Millipore Sigma Vibrant Logo

119136 Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem

SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: (2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine

View Products on Sigmaaldrich.com
119136
Preis & Verfügbarkeit

Übersicht

Replacement Information

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
119136-10MG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Glasflasche 10 mg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewAn adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
      Catalogue Number119136
      Brand Family Calbiochem®
      Synonyms(2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine
      References
      ReferencesBurgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
      Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
      Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
      Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
      Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
      Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.
      Product Information
      CAS number37739-05-2
      FormWhite solid
      Hill FormulaC₁₅H₂₀ClN₅O₄
      Chemical formulaC₁₅H₂₀ClN₅O₄
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetA1
      Primary Target K<sub>i</sub>2.3 nM
      Purity≥99% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      119136-10MG 04055977223323

      Documentation

      Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      Adenosine A1 Receptor Agonist II, CCPA - CAS 37739-05-2 - Calbiochem Analysenzertifikate

      TitelChargennummer
      119136

      Literatur

      Übersicht
      Burgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
      Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
      Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
      Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
      Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
      Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision28-March-2013 JSW
      Synonyms(2R,3R,4S,5R)-2-(2-chloro-6-(cyclopentylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 2-Chloro-N6-cyclopentyladenosine
      DescriptionAn adenosine analog that acts as a selective, high affinity agonist for Adenosine A1 receptor (A1R) (Ki = 800 pM; 2.3 µM, 18.8 µM, and 42 nM for human A1, A2A, A2B, A3 respectively). Shown to be centrally active following systemic administration and exhibits anti-convulsive effects. Also reported to inhibit adenylate cyclase activity in rat fat cell membrane (IC50 = 33 nM). Diminishes respiratory rhythm, reduces heart rate, and enhances the activity of KATP channels. Reduces norepinephrine release by about 50% in untreated and pertussis toxin treated hearts.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number37739-05-2
      Chemical formulaC₁₅H₂₀ClN₅O₄
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (100 mM) or H₂O (5 mM)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesBurgdorf, C. et al. 2005. J Cardiovasc Pharmacol. 45, 1.
      Klotz, K. N., et al. 2000. Naunyn Schmiedebergs Arch Pharmacol. 362, 382.
      Mironov, S., et al. 1990. J Neurophysiol. 81, 1.
      Monopoli, A., et al. 1994.Arzneimittelforschung. 44, 1305.
      Concas, A., et al. 1993. J Pharmacol Exp Ther. 267, 844.
      Lohse, M. J., et al. 1988. Nauryn Schmiedebergs Arch Pharmacol. 337, 687.
      Coffin, V. L., et al. 1987. J Pharmacol Exp Ther. 241, 76.